This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnston, S. R. D. Articles by Benz, C. C. Search for Related Content PubMed PubMed Citation Articles by Johnston, S. R. D. Articles by Benz, C. C.

Comparison of Estrogen Receptor DNA Binding in Untreated and Acquired Antiestrogen-resistant Human Breast Tumors¹

Academic Department of Biochemistry, Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, United Kingdom [S. R. D. J., M. D.]; Department of Medicine and Cancer Research Institute, University of California, San Francisco, California 94143-1270 [B. L., X. L., G. K. S., C. C. B.]; Universitat Frauenklinik, Heidelberg, Germany [M. K.]; and Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7884 [C. K. O.]

Preliminary studies have suggested that measuring the ability of immunoreactive 67-kDa estrogen receptor (ER) to bind DNA and form in vitro complexes with its cognate estrogen response element (ERE) might serve to identify breast tumors most likely to respond to antiestrogens like tamoxifen. Data from two different surveys of untreated primary breast tumors confirmed that only 67% (74 of 111) of ER-positive tumors express a receptor capable of forming ER-ERE complexes by gel-shift assay, with tumors of lower ER content having significantly reduced ER DNA-binding frequency (56%) relative to those of higher ER content (82%; P = 0.007). In contrast to these untreated tumors, a panel of 41 receptor-positive breast tumors excised after acquiring clinical resistance to tamoxifen during either primary (n = 26) or adjuvant therapy (n = 15) showed a significantly greater ER DNA-binding frequency, with nearly 90% capable of forming ER-ERE complexes (P < 0.02). To assess experimentally whether ER DNA-binding function is altered during the development of antiestrogen resistance, nude mouse MCF-7 tumor xenografts were analyzed before and after the acquisition of in vivo resistance to either tamoxifen or a pure steroidal antiestrogen, ICI 182,780. Tamoxifen-resistant MCF-7 tumors retained full expression of 67-kDa DNA-binding ER, and despite a markedly reduced ER content in the ICI 182,780-treated tumors, the expressed ER in these antiestrogen-resistant tumors exhibited full ability to form ER-ERE complexes. These findings indicate that breast tumors with acquired antiestrogen resistance continue to express ER of normal size and DNA-binding ability and suggest that the failure of antiestrogens to arrest tumor growth during emergence of clinical resistance results from an altered gene-regulatory mechanism(s) other than ER-ERE complex formation.

¹ Supported in part by the Sussan G. Komen Foundation, the Janet Landfear and Hazel P. Munroe Memorial Funds, and Grants R01-CA71468 and P50-CA58183 from the National Cancer Institute. S. R. D. J. was funded by a Cancer Research Campaign Clinical Research Training Fellowship.

² To whom requests for reprints should be addressed. Phone: 0171-352-8171, extension 2884 or 2745; Fax: 0171-352-5441.

³ Present address: J. W. Goethe University, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.

Received 3/19/97. Accepted 7/ 3/97.

This article has been cited by other articles:

				X. Lin, Y. Yu, H. Zhao, Y. Zhang, J. Manela, and D. A. Tonetti Overexpression of PKC{alpha} is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model Carcinogenesis, August 1, 2006; 27(8): 1538 - 1546. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche, S. Van Belle, F. De Winter, A. Signore, and C. Van de Wiele Early Prediction of Endocrine Therapy Effect in Advanced Breast Cancer Patients Using 99mTc-Depreotide Scintigraphy J. Nucl. Med., January 1, 2006; 47(1): 6 - 13. [Abstract] [Full Text] [PDF]

				D. F. Hayes Playing the Old Piano: Another Tune for Endocrine Therapy? J Natl Cancer Inst, November 5, 2003; 95(21): 1565 - 1567. [Full Text] [PDF]

				S. R. D. Johnston, J. Head, S. Pancholi, S. Detre, L.-A. Martin, I. E. Smith, and M. Dowsett Integration of Signal Transduction Inhibitors with Endocrine Therapy: An Approach to Overcoming Hormone Resistance in Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 524S - 532S. [Abstract] [Full Text] [PDF]

				R. I. NICHOLSON, I. R. HUTCHESON, M. E. HARPER, J. M. KNOWLDEN, D. BARROW, R. A. McCLELLAND, H. E. JONES, A. E. WAKELING, and J.M. W. GEE Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 104 - 115. [Abstract] [Full Text] [PDF]

				J. M. Schafer, E.-S. Lee, R. C. Dardes, D. Bentrem, R. M. O'Regan, A. De Los Reyes, and V. C. Jordan Analysis of Cross-Resistance of the Selective Estrogen Receptor Modulators Arzoxifene (LY353381) and LY117018 in Tamoxifen-stimulated Breast Cancer Xenografts Clin. Cancer Res., August 1, 2001; 7(8): 2505 - 2512. [Abstract] [Full Text] [PDF]

				E. S. Lee, J. M. Schafer, K. Yao, G. England, R. M. O’Regan, A. D. L. Reyes, and V. C. Jordan Cross-Resistance of Triphenylethylene-type Antiestrogens but not ICI 182,780 in Tamoxifen-stimulated Breast Tumors Grown in Athymic Mice Clin. Cancer Res., December 1, 2000; 6(12): 4893 - 4899. [Abstract] [Full Text]

				S. R. D. Johnston, B. Lu, G. K. Scott, P. J. Kushner, I. E. Smith, M. Dowsett, and C. C. Benz Increased Activator Protein-1 DNA Binding and c-Jun NH2-Terminal Kinase Activity in Human Breast Tumors with Acquired Tamoxifen Resistance Clin. Cancer Res., February 1, 1999; 5(2): 251 - 256. [Abstract] [Full Text] [PDF]